ReviewCurrent opinion in immunology2019
Pertussis vaccines and protective immunity.
Review in Current opinion in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Seroprevalence of IgG antibodies against pertussis toxin in the Chinese population: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Immunogenicity and safety of co-purified diphtheria, tetanus and acellular pertussis vaccine in 6-year-old Chinese children.Nature communications · 2025Trial
- Half-life Estimation of Pertussis-Specific Maternal Antibodies in (Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis Vaccination.The Journal of infectious diseases · 2023Trial
- Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.The Journal of clinical investigation · 2020Trial
- Seroprevalence of diphtheria, tetanus, pertussis among healthcare workers (HCWs) - A cross-sectional study at the National Centre for Infectious Diseases and Tan Tock Seng Hospital, Singapore.Human vaccines & immunotherapeutics · 2026Article
- Post-exposure booster vaccination recalls vaccine-induced memory and accelerates Bordetella pertussis clearance in murine lungs and trachea.Scientific reports · 2026Article
- Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection Model.medRxiv : the preprint server for health sciences · 2026Article
- Cohort study on transplacental antibody transfer to fetal growth-restricted infants of tdap-vaccinated pregnant women, study protocol.BMC pregnancy and childbirth · 2026Article
- Review
- Antigen-specific TScience advances · 2026Article
- CD4+ T-cell immunity toDiscover immunity · 2026Review
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- Innovative adjuvant strategies for next-generation pertussis vaccines.Human vaccines & immunotherapeutics · 2025Review
- Immunologic profiling of the infant immune response to whole-cell and acellular pertussis vaccines.NPJ vaccines · 2025Article
- Impact of pertussis vaccination on PT-IgG levels and clinical characteristics in 3-12-month-old infants with acute pertussis.European journal of pediatrics · 2025Article
- Variation in virulence between three representativemSphere · 2025Article
- In silico design and evaluation of a multiepitope vaccine against Bordetella pertussis: structural, immunological, and biological properties.Genomics & informatics · 2025Article
- Highlights of the 14th InternationalmSphere · 2025Article
- Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria.Materials today. Bio · 2024Review
- Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite high vaccine coverage, reported cases of pertussis have increased steadily over the last twenty years. This resurgence has stimulated interest in host responses to pertussis infection and vaccination with the goal of developing more effective next-generation vaccines and vaccination strategies. Optimal protection against Bordetella pertussis appears to be multifactorial requiring both humoral and cellular responses. Natural infection and whole-cell pertussis vaccination induce Th1 and Th17-dominated responses. In contrast, acellular vaccines induce Th2-dominated responses. Available immunological data indicate that while antibodies provide protection against disease, Th1 and Th17-mediated immune responses are required for bacterial clearance and long-lasting protection. The nature of the priming in children appears to be important in modulating bias and durability of immune responses required to provide protection against B. pertussis. This review summarizes the current understanding of differences in immune responses and their role in protection against B. pertussis following infection or vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.